Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia.
Latagliata R, Breccia M, Fazi P, Iacobelli S, Martinelli G, Di Raimondo F, Sborgia M, Fabbiano F, Pirrotta MT, Zaccaria A, Amadori S, Caramatti C, Falzetti F, Candoni A, Mattei D, Morselli M, Alimena G, Vignetti M, Baccarani M, Mandelli F.
Latagliata R, et al. Among authors: breccia m.
Br J Haematol. 2008 Dec;143(5):681-9. doi: 10.1111/j.1365-2141.2008.07400.x. Epub 2008 Oct 20.
Br J Haematol. 2008.
PMID: 18950458
Free article.
Clinical Trial.